000075515 001__ 75515
000075515 005__ 20200117221608.0
000075515 0247_ $$2doi$$a10.3390/jcm7080220
000075515 0248_ $$2sideral$$a107947
000075515 037__ $$aART-2018-107947
000075515 041__ $$aeng
000075515 100__ $$aDiaz-Morales, N.
000075515 245__ $$aMitochondrial DNA Haplogroup JT is Related to Impaired Glycaemic Control and Renal Function in Type 2 Diabetic Patients
000075515 260__ $$c2018
000075515 5060_ $$aAccess copy available to the general public$$fUnrestricted
000075515 5203_ $$aThe association between mitochondrial DNA (mtDNA) haplogroup and risk of type 2 diabetes (T2D) is undetermined and controversial. This study aims to evaluate the impact of the main mtDNA haplogroups on glycaemic control and renal function in a Spanish population of 303 T2D patients and 153 healthy controls. Anthropometrical and metabolic parameters were assessed and mtDNA haplogroup was determined in each individual. Distribution of the different haplogroups was similar in diabetic and healthy populations and, as expected, T2D patients showed poorer glycaemic control and renal function than controls. T2D patients belonging to the JT haplogroup (polymorphism m.4216T>C) displayed statistically significant higher levels of fasting glucose and HbA(1c) than those of the other haplogroups, suggesting a poorer glycaemic control. Furthermore, diabetic patients with the JT haplogroup showed a worse kidney function than those with other haplogroups, evident by higher levels of serum creatinine, lower estimated glomerular filtration rate (eGFR), and slightly higher (although not statistically significant) urinary albumin-to-creatinine ratio. Our results suggest that JT haplogroup (in particular, change at position 4216 of the mtDNA) is associated with poorer glycaemic control in T2D, which can trigger the development of diabetic nephropathy.
000075515 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B33-17R$$9info:eu-repo/grantAgreement/ES/ISCIII/CIBERehd/CB06-04-0071$$9info:eu-repo/grantAgreement/ES/ISCIII/FI14-00125$$9info:eu-repo/grantAgreement/ES/ISCIII/FI14-00350$$9info:eu-repo/grantAgreement/ES/ISCIII/PI14-00070$$9info:eu-repo/grantAgreement/ES/ISCIII/PI16-0301$$9info:eu-repo/grantAgreement/ES/ISCIII/PI16-1083$$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-00166
000075515 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000075515 590__ $$a5.688$$b2018
000075515 591__ $$aMEDICINE, GENERAL & INTERNAL$$b15 / 159 = 0.094$$c2018$$dQ1$$eT1
000075515 592__ $$a2.274$$b2018
000075515 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000075515 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000075515 700__ $$aLopez-Domenech, S.
000075515 700__ $$aIannantuoni, F.
000075515 700__ $$0(orcid)0000-0002-3217-1424$$aLopez-Gallardo, E.$$uUniversidad de Zaragoza
000075515 700__ $$aSola, E.
000075515 700__ $$aMorillas, C.
000075515 700__ $$aRocha, M.
000075515 700__ $$0(orcid)0000-0002-0269-7337$$aRuiz-Pesini, E.$$uUniversidad de Zaragoza
000075515 700__ $$aVictor, V.M.
000075515 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000075515 773__ $$g7, 8 (2018), 220$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000075515 8564_ $$s318054$$uhttps://zaguan.unizar.es/record/75515/files/texto_completo.pdf$$yVersión publicada
000075515 8564_ $$s103177$$uhttps://zaguan.unizar.es/record/75515/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000075515 909CO $$ooai:zaguan.unizar.es:75515$$particulos$$pdriver
000075515 951__ $$a2020-01-17-21:47:29
000075515 980__ $$aARTICLE